Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1992;3(1-2):91-115.

Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells

Affiliations
  • PMID: 1532331
Review

Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells

E Eigenbrodt et al. Crit Rev Oncog. 1992.

Abstract

As a common characteristic of tumor cells, as well as of normal proliferating cells in the G1-phase of cell cycle, one finds constitutive high levels of all the glycolytic metabolites arising between glucose 6-phosphate and phosphoenolpyruvate. Thus, it is that the phosphometabolites fructose 1,6-bisphosphate, ribose 5-P, P-ribose-PP, NAD, GTP, CTO, UTP, UDP-glucose, glycerol 3-P, glycerol phosphocholine and glycerol phosphoethanolamine are useful in the 31P-nuclear magnetic resonance (NMR) detection of solid tumors in animals and man. This expansion of phosphometabolites is achieved during tumor formation as a result of reductions in levels of enzymes degrading phosphometabolites, owing to the decline in the glycerol 3-P hydrogen shuttle, and as a consequence of alterations in the glycolytic isoenzyme equipment. Tumor cells typically express a particular isoenzyme of pyruvate kinase called type M2 (K) at high levels. This isoenzyme is subject to a complex regulation by amino acids, by fructose 1,6-bisphosphate, and by hormonal- and oncogene-dependent phosphorylation. Pyruvate kinase type M2 is a substrate for the oncogene encoded PP60v-src-tyrosine kinase. A drastic decrease in the affinity for its substrate phosphoenolpyruvate found after transformation by the src-oncogene can be explained as a consequence of the phosphorylation of pyruvate kinase in serine and tyrosine. These phosphorylations induce the breakdown of tetrameric pyruvate kinase to the trimeric and dimeric forms. Unlike the tetrameric form, the dimeric form as a low affinity for phosphoenolpyruvate. Partial inactivation of pyruvate kinase and enolase on the one hand, and a hyperactivation of hexokinase and phosphofructokinase on the other hand, lead to an expansion of all metabolites. Only when these metabolites attain high levels, thereby assuring a sufficient supply of metabolites for RNA, DNA, lipid, and complex carbohydrate synthesis, can cell proliferation proceed. This accumulation of metabolites in the G1-phase cells has been termed a "metabolic budget system" because it senses not only the actual nutrient levels, but also the supply over a period of time. Monoclonal antibodies specific for the dimeric form of pyruvate kinase type M2 can be used for the immunohistological detection of tumor cells. The amount of the dimeric form in tumor cells closely correlates with the degree of malignancy and can be used for a nonspecific detection of tumors based on assays performed with patient's plasma.

PubMed Disclaimer

Similar articles

Cited by

  • Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.
    Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, Malstrom S, Khan TM, Kung C, Skoumbourdis AP, Veith H, Southall N, Walsh MJ, Brimacombe KR, Leister W, Lunt SY, Johnson ZR, Yen KE, Kunii K, Davidson SM, Christofk HR, Austin CP, Inglese J, Harris MH, Asara JM, Stephanopoulos G, Salituro FG, Jin S, Dang L, Auld DS, Park HW, Cantley LC, Thomas CJ, Vander Heiden MG. Anastasiou D, et al. Nat Chem Biol. 2012 Oct;8(10):839-47. doi: 10.1038/nchembio.1060. Nat Chem Biol. 2012. PMID: 22922757 Free PMC article.
  • Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F(0)F(1)-ATPase.
    Salomon AR, Voehringer DW, Herzenberg LA, Khosla C. Salomon AR, et al. Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14766-71. doi: 10.1073/pnas.97.26.14766. Proc Natl Acad Sci U S A. 2000. PMID: 11121076 Free PMC article.
  • Tumor M2-PK: A novel urine marker of bladder cancer.
    Liu W, Woolbright BL, Pirani K, Didde R, Abbott E, Kaushik G, Martin P, Hamilton-Reeves J, Taylor JA 3rd, Holzbeierlein JM, Anant S, Lee EK. Liu W, et al. PLoS One. 2019 Jun 27;14(6):e0218737. doi: 10.1371/journal.pone.0218737. eCollection 2019. PLoS One. 2019. PMID: 31246990 Free PMC article.
  • The roles of molecular chaperones in regulating cell metabolism.
    Binder MJ, Pedley AM. Binder MJ, et al. FEBS Lett. 2023 Jul;597(13):1681-1701. doi: 10.1002/1873-3468.14682. Epub 2023 Jun 16. FEBS Lett. 2023. PMID: 37287189 Free PMC article. Review.
  • Lipids and prostate cancer.
    Suburu J, Chen YQ. Suburu J, et al. Prostaglandins Other Lipid Mediat. 2012 May;98(1-2):1-10. doi: 10.1016/j.prostaglandins.2012.03.003. Epub 2012 Apr 5. Prostaglandins Other Lipid Mediat. 2012. PMID: 22503963 Free PMC article. Review.

Publication types

MeSH terms

LinkOut - more resources